Captopril in hypertension; seven years later

Area of Science:

• Cardiology
• Pharmacology
• Hypertension Management

Background:

• Captopril, an angiotensin-converting enzyme (ACE) inhibitor, was initially associated with frequent side effects due to high dosages and severe patient conditions.
• Optimized dosing strategies and the concurrent use of diuretics have since improved captopril's safety profile.
• Postmarketing surveillance is crucial for evaluating long-term drug efficacy and safety in real-world clinical settings.

Purpose of the Study:

• To assess the long-term antihypertensive efficacy and safety of captopril in a large, diverse patient population.
• To evaluate the impact of adjusted dosing regimens and diuretic co-administration on captopril's effectiveness and tolerability.
• To document captopril's performance in routine clinical practice, including patients with comorbidities like impaired renal function.

Main Methods:

• A worldwide postmarketing surveillance study involving 6,737 hypertensive patients.
• Longitudinal data collection for 3,219 patients treated for at least 1 year.
• Analysis of patient demographics, baseline characteristics (including renal function and prior therapies), captopril dosage, and adverse event reporting.

Main Results:

• Long-term antihypertensive efficacy was maintained with a mean captopril dose of approximately 150 mg/day.
• Captopril demonstrated satisfactory blood pressure control, particularly when used with a diuretic.
• The cumulative frequency of drug discontinuation due to adverse reactions within 12 months was significantly reduced to 5.8%.

Conclusions:

• Optimized captopril dosing, often in conjunction with diuretics, maintains antihypertensive efficacy while significantly improving the safety profile.
• Captopril is a well-tolerated and effective long-term treatment option for hypertension, even in patients with comorbidities.
• Postmarketing surveillance confirms the benefits of captopril in managing hypertension in a broad patient population.